NAD+ in sport: energy claims, recovery studies and risks

Why NAD+ is discussed as an energy intervention

NAD+ has a genuine role in cellular energy metabolism, which makes it an appealing name in discussions of fatigue, endurance and recovery. The leap from essential biology to a useful intervention is the problem. Many essential substances do not improve performance simply because more is supplied. For a sports claim, the relevant question is whether a defined intervention changes an outcome in the intended population, with acceptable harms. General tiredness, a metabolic disease and normal training fatigue are also different problems and should not be collapsed into one NAD-deficiency narrative.

NAD+ is not a peptide, and its precursors are not identical

Nicotinamide adenine dinucleotide is a coenzyme, not an amino-acid-chain peptide. Nicotinamide riboside, abbreviated NR, is a precursor used in some human studies. NRPT combines NR with pterostilbene. Those interventions differ from directly supplied NAD+, and a result for one cannot automatically validate another. Formulation and delivery also influence how a substance is handled. A product's milligram label does not establish that an intracellular target changed, let alone that a person can produce more power or recover faster.

Specific human studies, with their limits

Grant and colleagues' 2019 Frontiers in Aging Neuroscience pilot included 11 men and measured plasma and urinary metabolites during NAD+ administration. It was a small metabolism study, not a demonstration of stronger or faster athletes.

Elhassan and colleagues' 2019 Cell Reports crossover trial in 12 older men studied NR. It found changes in the muscle NAD-related metabolome without improved mitochondrial bioenergetics. Jensen and colleagues' 2022 JCI Insight randomised trial studied NRPT in 32 older people after experimental muscle injury and did not find improved muscle-stem-cell recruitment or the tested recovery measures. These are useful named studies, but their interventions and populations differ from a sports-product claim.

What a plausible advantage would need to show

The research interest is whether NAD-related interventions can help a defined problem in a defined group. That is more specific than a promise of universal energy or anti-ageing. A sporting advantage would need functional endpoints such as repeatable exercise capacity or recovery, rather than only a blood metabolite. A biochemical change can be real without being large enough, relevant enough or in the right tissue to improve performance. Conversely, a negative finding in one precursor study does not prove that every possible NAD intervention is ineffective; it limits that particular claim.

Risks include formulation and quality, not only the molecule

The FDA has warned about inappropriate ingredients in sterile NAD+ compounding and reported reactions including chills, shaking, vomiting and fatigue, consistent with excessive endotoxin exposure. This is a product-quality warning, not proof that all those reactions are intrinsic to pure NAD+. It shows why biological familiarity cannot guarantee the safety of a supplied preparation. Long-term sporting use, interactions and individual tolerability also need evidence. A claimed energy benefit does not offset an unidentified product or a serious adverse reaction.

How to evaluate a recovery claim

Identify exactly what was studied before reading the result: NAD+, NR or a multi-ingredient intervention. Then check whether the result concerns metabolites, tissue findings or actual function. A study in older people cannot be presented as definitive proof in young trained athletes, and a product name is not a diagnosis of deficiency. Persistent unexplained fatigue warrants clinical assessment rather than an automatic assumption that an energy coenzyme is missing. Current medication and sport-method rules also require a separate authoritative check; an ingredient label alone cannot settle them.